Skip to content
Menu

Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

Benzinga Newsdesk 4 weeks ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.

Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.

Read at benzinga.com

← All stock news